In adults with granulomatous anterior uveitis and positive HLA-B27, should topical steroids alone be initiated or systemic immunosuppression added immediately

What is known

- Acute anterior uveitis in spondyloarthropathy responds well to frequent topical corticosteroids and cycloplegics; roughly 13–19% are resistant to topical therapy and may need periocular, intraocular, or systemic corticosteroids. ¹ - Current first-line therapy for HLA-B27 acute anterior uveitis is a cycloplegic plus very frequent potent topical corticosteroids tapered over several weeks, with systemic NSAIDs, corticosteroids, or immunomodulatory therapy added in severe or recurrent cases. ^2,3 - If ocular inflammation is resistant to steroids or steroid adverse effects occur, systemic immunosuppression should be considered, more likely in HLA-B27-positive patients. ^4,5 - In an IBD-associated cohort, HLA-B27-positive anterior uveitis was more refractory to corticosteroids and more likely to require systemic cytotoxic immunosuppression. ⁶ - Topical/local corticosteroids carry risk of steroid-response elevated intraocular pressure (up to ~30%) and cataract, which can necessitate added pressure-lowering therapy or steroid cessation. ^2,3

What is unknown / caveats

- Excerpts describe HLA-B27 anterior uveitis as typically non-granulomatous and do not address a granulomatous presentation - Because a granulomatous presentation is atypical for HLA-B27 disease, infectious and systemic granulomatous causes (tuberculosis, syphilis, herpetic uveitis, sarcoidosis) must be excluded before systemic corticosteroids or immunomodulators are started. Systemic immunosuppression given for undiagnosed ocular tuberculosis, syphilis, or herpetic disease risks irreversible vision loss or disseminated infection - Evidence is narrative reviews plus one small 1994 case series; no trial defines when to add systemic therapy up front - The retrieved sources do not specify management for a granulomatous (rather than non-granulomatous) anterior uveitis presentation.

## References

1. Ebrahimiadib N, Berijani S, Ghahari M, Pahlaviani FG. Ankylosing Spondylitis. J Ophthalmic Vis Res. 2021. PMID: 34394873.

2. Wakefield D, Clarke D, McCluskey P. Recent Developments in HLA B27 Anterior Uveitis. Front Immunol. 2020. PMID: 33469457.

3. Narain S, Gupta P, Pyare R, Shroff D, Rath PD. Recent updates in human leukocyte antigen B27-associated uveitis. Indian J Ophthalmol. 2026. PMID: 42200732.

4. Calvo P, Pablo L. Managing IBD outside the gut: ocular manifestations. Dig Dis. 2013. PMID: 24030231.

5. Mady R, Grover W, Butrus S. Ocular complications of inflammatory bowel disease. ScientificWorldJournal. 2015. PMID: 25879056.

6. Soukiasian SH, Foster CS, Raizman MB. Treatment strategies for scleritis and uveitis associated with inflammatory bowel disease. Am J Ophthalmol. 1994. PMID: 7977573.

For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.

---

_Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct._